What does the latest study recommend for osteoporosis management after completing five years of alendronate therapy?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 15, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Management After 5 Years of Alendronate Therapy

After completing 5 years of alendronate therapy, reassess fracture risk and consider a bisphosphonate holiday for patients at low-to-moderate fracture risk, while continuing treatment for those who remain at high risk. 1, 2

Risk Stratification at 5 Years

The decision to continue or pause alendronate hinges on current fracture risk assessment:

Continue Alendronate (up to 10 years total) if:

  • T-score remains ≤ -2.5 at spine or hip
  • History of fragility fractures during treatment
  • New vertebral fractures on imaging
  • Very high risk features: severe or multiple vertebral fractures, recent fractures, or very low BMD 2

Consider Bisphosphonate Holiday if:

  • T-score improved to > -2.5
  • No fractures during treatment
  • Low-to-moderate fracture risk by country-specific assessment tools (FRAX, etc.) 1

The Bisphosphonate Holiday Approach

A bisphosphonate holiday means temporary discontinuation for up to 5 years, based on strong evidence from randomized trials showing alendronate's residual protective effects persist after stopping 1, 3. This approach balances continued fracture protection against rare but serious long-term risks (atypical femoral fractures, osteonecrosis of jaw).

During the Holiday:

  • Reassess fracture risk every 2-4 years with BMD measurement and clinical evaluation 1
  • Restart therapy earlier than 5 years if:
    • BMD declines beyond the least significant change of your DXA machine
    • New fragility fracture occurs
    • Clinical circumstances change (new risk factors, glucocorticoid use) 2

Evidence Supporting This Strategy:

The landmark FLEX trial demonstrated that women discontinuing alendronate after 5 years showed moderate BMD decline (-2.4% hip, -3.7% spine) but no increased risk of nonvertebral fractures compared to those continuing treatment 3. However, there was a 55% reduction in clinical vertebral fractures (2.4% vs 5.3%) among those who continued, suggesting very high-risk patients benefit from extended therapy 3.

Critical Distinction: Alendronate vs Other Agents

This holiday concept applies ONLY to bisphosphonates (alendronate, risedronate, zoledronic acid). The evidence is strongest for alendronate and zoledronic acid due to their long skeletal retention 1.

Never take a holiday from:

  • Denosumab: Stopping causes rapid BMD loss (6.6% spine, 5.3% hip in 12 months) and increased vertebral fracture risk due to rebound bone turnover 1. If denosumab must be stopped, transition immediately to bisphosphonates 2
  • Teriparatide/Abaloparatide: Must be followed by antiresorptive therapy to maintain gains 2
  • Romosozumab: Requires subsequent long-term therapy 2

Monitoring Strategy

For patients continuing alendronate beyond 5 years:

  • DXA every 1-3 years at spine and hip 1
  • Bone turnover markers (serum CTX or P1NP) can identify non-adherence or treatment failure 2
  • Expected BMD increases: lumbar spine +7%, total hip +5% over initial treatment period 1, 4

For patients on holiday:

  • DXA every 2-4 years
  • Monitor for height loss (suggests vertebral fracture)
  • Reassess clinical risk factors

Common Pitfalls to Avoid

  1. Don't automatically stop at 5 years: High-risk patients (T-score ≤ -2.5, prior fractures, multiple risk factors) should continue therapy 2

  2. Don't confuse alendronate with denosumab: Denosumab requires continuous therapy or immediate transition to bisphosphonates—never a holiday 1

  3. Don't ignore the 3-year rule for zoledronic acid: IV zoledronic acid has a shorter reassessment period (3 years vs 5 years for oral bisphosphonates) due to its potency and dosing schedule 1

  4. Don't forget calcium and vitamin D: All patients need adequate calcium (1200 mg/day) and vitamin D (800-1000 IU/day) regardless of pharmacologic therapy status 1

Special Considerations

Atypical femoral fractures (AFF): Risk increases with duration beyond 5 years (~3 per 100,000 at 2 years to ~50 per 100,000 at >8 years), but this remains 100-fold lower than typical osteoporotic hip fractures prevented by treatment 1. The holiday strategy helps mitigate this rare complication.

Osteonecrosis of jaw (ONJ): Risk is 0.001-0.21% in osteoporosis patients, higher with longer duration (>4 years) 1. Maintain good dental hygiene; consider deferring invasive dental procedures during active treatment when possible.

References

2
Guideline

american association of clinical endocrinologists/american college of endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis- 2020 update <i>executive summary</i>.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologist, 2020

Related Questions

What is the recommended management for osteoporosis after completing five years of alendronate therapy?
In a 74-year-old woman with osteoporosis who has been treated with alendronate (Fosamax) for five years and now has persistent osteoporosis on repeat DEXA at multiple sites, what is the next step in management?
In a hospice patient with limited life expectancy who has been taking alendronate for more than three years, should the medication be discontinued?
Is a monthly dose of 150 mg alendronate effective for treating osteoporosis in adults?
Which osteoporosis medication should a female patient start after discontinuing alendronate (Fosamax)?
In a male patient with chronic kidney disease (renal failure), when is testosterone replacement therapy indicated, how should it be initiated and titrated, and what risks and monitoring are required?
What is the recommended management for osteoporosis after completing five years of alendronate therapy?
What is the likelihood of Stevens-Johnson syndrome occurring with lamotrigine in a patient who previously experienced Stevens-Johnson syndrome with terbinafine (Lamisil)?
Should furosemide (Lasix) be held in a hospitalized patient with hepatic encephalopathy who has hypotension and bradycardia (55–60 bpm)?
Can a proton‑pump inhibitor be taken together with rifaximin (Xifaxan) without interaction?
What is the likely cause of sharp neck pain radiating to the eyebrow on sneezing and how should it be evaluated and managed?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.